Physician profile
John L Markert
NPI 1003922923
$7,605.30
in general payments reported to CMS, 2019-2025
42 companies · $850 in 2025
The $850 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $1,054 · 2021: $1,593 · 2022: $1,129 · 2023: $845 · 2024: $712 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,038.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $999.17 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $871.37 | 2019-2025 | |
| Abbvie INC. | $543.81 | 2021-2025 | |
| Amgen INC. | $489.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $416.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.04 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Synjardy |
| Sanofi-Aventis U.S. LLC | $358.59 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.30 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $260.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $256.50 | 2019-2022 | |
| Astellas Pharma US INC | $229.63 | 2019-2023 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $168.07 | 2019-2022 | |
| Allergan, INC. | $155.57 | 2019-2020 | |
| Exact Sciences Corporation | $130.44 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Markert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.